Pulmonary function between 40 and 80 years of age.

Spirometry is the most frequently performed lung function test. To determine a normal range of spirometry results, reference formulas are used. Predicted values play an important role in establishing whether the volumes measured in an individual fall within a range to be expected in a healthy person of the same gender, height, and age. Such standards enable to assess the development of the respiratory system in the youth, the early recognition of the influence of a disease on the respiratory system and the influence of environmental factors on lung function. The objective of the present study was to estimate lung function prediction equations and to identify appropriate normal reference values for the Lublin Region local population of adults. We addressed the issue by analyzing the data from a lung function screening program conducted in the Lublin Region of Poland. Pulmonary function of adults aged 40-80 years was assessed from the measurements of forced vital capacity (FVC) and forced expired volume in the first second (FEV(1)) in 136 adults. Reference values of FVC and FEV(1) for females and males were calculated by linear multiple regressions with age and height used as predictors. Different equations were compared to show their reliability when applied to the local population. The results were as follows. In females, the mean FEV(1) was 2.856 +/-0.534 (L) (113.7 +/-14.3%) and the mean FVC was 3.517 +/-0.662 (L) (118.5 +/-14.1%), in males, 3.913 +/-0.773 (L) (110.9 +/-15.1%), 4.922 +/-0.941 (L) (112.1 +/-14.1%), respectively. The estimated prediction equations were: for the FVC - for females - FVC (L) = 0.0528 (height) - 0.0262 (age) - 3.676 and for males - FVC = 0.0756 (height) - 0.0649 (age) - 4.904; and for the FEV(1) - for females - FEV(1) (L) = 0.0378 (height) - 0.0282 (age) - 1.799 and for males - FEV(1) (L) = 0.0553 (height) - 0.0553 (age) - 2.874. Units are years for age and centimeters for height. In conclusion, the analysis of the lung function data showed that there were significant difficulties in determining the appropriate reference values of FEV(1) and FVC. The predicted FEV(1) and FVC values derived from equations based on the ECSC (1) reference populations are considerably lower than those calculated in the present study, re-emphasizing the need to be cautious when applying the ECSC reference values for the local Lublin population. There seems to be a need for a constant refinement of spirometric standards.

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.

AIMS/HYPOTHESIS: Insulin resistance is associated with abnormalities in lipid and glucose metabolism, which are major components of metabolic syndrome and risk factors for vascular disease. This study examined the effect of tesaglitazar (Galida), a novel, dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, on lipid and glucose metabolism in patients with evidence of insulin resistance. METHODS: A 12-week, multicentre, randomised, double-blind, placebo-controlled, dose-finding study compared the efficacy and safety of oral tesaglitazar (0.1, 0.25, 0.5 and 1.0 mg/day) and placebo in 390 non-diabetic patients with hypertriglyceridaemia (plasma triglyceride concentration >1.7 mmol/l) and abdominal obesity (waist-to-hip ratio >0.90 for men and >0.85 for women). RESULTS: A 1.0-mg dose of tesaglitazar reduced fasting triglycerides (the primary endpoint) by 37% (95% CI: -43% to -30%; p<0.0001), non-HDL-cholesterol by 15% (95% CI: -20% to -10%; p<0.0001) and NEFA by 40% (95% CI: -51% to -27%; p<0.0001), and increased HDL-cholesterol by 16% (95% CI: 8 to -24%; p<0.0001). At the end of treatment there was a dose-dependent increase in patients with pattern A LDL particle diameter (40% at baseline vs 87% at 12 weeks for tesaglitazar 1.0 mg). Tesaglitazar produced significant reductions in fasting insulin concentration (-35%; p<0.0001) and plasma glucose concentration (-0.47 mmol/l; p<0.0001). Respiratory infection and gastrointestinal symptoms were the most common adverse events and were similarly frequent in all groups. CONCLUSIONS/INTERPRETATION: Tesaglitazar was well tolerated and produced significant, dose-dependent improvements in lipid and glucose metabolism and insulin sensitivity. Tesaglitazar may have the potential to prevent vascular complications and delay progression to diabetes in these patients.

Prevalence of obesity in Poland.

Obesity is an important health problem in Poland affecting adolescents and adults. A study of a Lower Silesian population aged 20-40 years (25 400 participants), between 1993 and 2003, showed an increase in obese women from 8.9% to 15.0%, but no change in men (6.3% vs. 6.5%, respectively). Obesity occurs more frequently in girls and women (6% and 15%) compared to boys and men (4.0% and 6.5%, respectively). Estimation of obesity prevalence in various parts of Poland seems to be regionally dependent; the highest prevalence of obesity was observed in eastern regions of Poland.

[The prevalence of type II diabetes mellitus in rural urban population over 35 years of age in Lublin region (Eastern Poland)]. / Badania nad wystepowaniem cukrzycy typu 2 w populacji powyzej 35 roku zycia na wsi i w miescie w regionie lubelskim.

The prevalence of type 2 diabetes mellitus (DM 2) has increased dramatically in the last decade. Data relating to the number of undetected cases of diabetes are underestimated. The aim of the study was to evaluate the prevalence of DM 2, obesity, hypertension, and lipid disturbances in a representative group of urban and rural population in the Lublin region (Eastern Poland). The study was performed in 1998-2001. A two-layer draw was applied: two groups of 3000 people were drawn from the population of Lublin town and from the rural areas each comprising 100,000 inhabitants. In all subjects physical examination was performed and body weight, height, and blood pressure measurements were obtained. Blood samples were taken from the basilic vein to estimate: blood glucose, lipids and insulin concentration. Venous blood glucose concentration was measured using a Glucotrend glucometer. Oral glucose tolerance test (OGTT) after a 75 g-glucose load was performed in subjects without previously diagnosed diabetes mellitus and when the fasting blood glucose was < 8.0 mmol/l (144 mg/l). The LDL-cholesterol level was calculated according to Friedewald formula. DM 2 was identified according to the WHO criteria from 1985. Obesity and hypertension were diagnosed according to the new WHO criteria (Body Mass Index > or = 30 kg/m2, blood pressure > or = 140/90 mm Hg). 3782 subjects: 1809 in the rural area and 1973 in Lublin town were examined. The response rate among rural and urban population was 60.3% and 65.8% respectively. The prevalence of DM 2 was assessed in 17.6% of rural and in 14.1% of urban population. 75% of diabetics in the rural areas and 56% in the town were the newly diagnosed cases. We found impaired glucose tolerance in 30.3% of rural and in 21.6% of urban population, BMI > or = 30 kg/m2 in 30.8% and 30.1%, hypertension in 69.4% (29.2% newly diagnosed) and 68.6% (27.7% newly diagnosed), hypercholesterolaemia (total cholesterol > or = 5.2 mmol/l (200 mg/dl)) in 66.4% and 60%, hyper-LDL-cholesterolaemia (> or = 3.5 mmol/l (135 mg/dl)) in 57.3% and 52.6%, hypo-HDL--cholesterolaemia in 21.7% and 31.4%, hypertriglyceridemia (> or = 2.3 mmol/l (200 mg/dl)) in 15.1% and 22% respectively. This finding indicates the urgent need for introducing a national program for early diagnosis and prevention of DM 2 and concomitant metabolic disturbances.

[Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes]. / Ocena skutecznosci, bezpieczenstwa i tolerancji glimepirydu (Amaryl) u pacjentów z cukrzyca typu 2.

UNLABELLED: Glimepiride is a new long-acting the third generation sulfonylurea given once daily. The aim of this study was to evaluate the efficacy, safety and tolerability of glimepiride given as monotherapy in type 2 diabetic patients. A total of 142 patients (65 women and 77 men; mean +/- SD: age 57 +/- 8.5 years, duration of diabetes 64.4 +/- 57.7 months, BMI 28.7 +/- 3.6 kg/m2) were treated during 12 weeks with glimepiride (Amaryl). Glimepiride was forced titrated 0.5-7.0 mg once daily based on efficacy. Statistical analysis our results showed significant (p < 0.001) decrease of average fasting blood glucose, twenty-four hour plasma glucose values and HbA1c significantly lower. Systolic and diastolic blood pressure was also significantly (p < 0.001; p < 0.03) lower. There was a trend to lower serum cholesterol and triglyceride levels. The other laboratory values did not change during this study. No differences were registered in body weight. Safety was assessed by evaluating vital signs, laboratory values and the occurrence of adverse events. The frequency of hypoglycaemic events was very rare (0.7%). The percentage of patients with adverse drug reactions was 6.3%. The tolerance of glimepiride was good. CONCLUSION: This study demonstrates that glimepiride is effective, safe and well tolerated in improving glycaemic control in patients with type 2 diabetes.